RxDoctor Payments Data

Philip Chase, MD

Family Medicine · Auburn, INNPI 1225036007

Payments from drug & device makers

$1,803in general payments, 2019–2025

Across 111 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$240
  • AstraZeneca$224
  • Lilly USA, LLC$158
  • Novo Nordisk$151
  • Abbott$108
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$92
  • plus $831 from 25 others

What the payments were for

  • Food & beverage$1,77699%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,803 in reported general payments places this provider in the 70th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$110,877
Medicare patients
369
Services billed
2,325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban213$229,635
OzempicSemaglutide182$220,336
FarxigaDapagliflozin Propanediol163$162,490
JardianceEmpagliflozin127$139,818
Trelegy ElliptaFluticasone/Umeclidin/Vilanter139$120,667
XareltoRivaroxaban33$50,845
TrulicityDulaglutide41$48,258
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr43$27,723
MyrbetriqMirabegron23$26,793
JanuviaSitagliptin Phosphate24$26,202
Breo ElliptaFluticasone/Vilanterol52$25,951
RybelsusSemaglutide21$24,028
MounjaroTirzepatide20$22,985
Xultophy 100-3.6Insulin Degludec/Liraglutide17$22,062
ProliaDenosumab13$21,673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$151$266,427220 claims
PfizerEliquis$73$229,635213 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$224$185,576206 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$74$178,320252 claims
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Stiolto Respimat$37$170,221171 claims
Lilly USA, LLCTrulicity, Mounjaro$158$71,24461 claims
Astellas Pharma US IncMyrbetriq$64$26,79323 claims
AmgenProlia$66$21,67313 claims
AbbVieLinzess, Creon$240$20,90428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Auburn

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →